---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-002470"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:42:42.658397+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q4 net loss $93.3M; UKONIQ revenue $2.3M; FDA partial hold on U2

## Summary
- Net loss Q4 2021 $93.3M ($88.2M Q4 2020); full year net loss $348.1M ($279.4M 2020).
- Product revenue from UKONIQ net $2.3M in Q4, $6.5M for full year 2021.
- Cash, equivalents & securities $350.3M at Dec 31, 2021; funds operations into 2023.
- FDA partial clinical hold on U2 (ublituximab + umbralisib) studies in CLL/NHL; ODAC meeting expected March/April 2022.
- FDA accepted BLA for ublituximab in RMS (PDUFA Sept 28, 2022); BLA/sNDA for U2 in CLL/SLL pending ODAC.

## SEC filing metadata
- accession: 0001558370-22-002470
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000155837022002470/0001558370-22-002470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000155837022002470/tgtx-20220301x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-002470
- JSON: https://secwatch.observer/filing/0001558370-22-002470.json
- Plain text: https://secwatch.observer/filing/0001558370-22-002470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.